Patents Examined by Joan Ellis
  • Patent number: 5480796
    Abstract: An isolated receptor protein for human B cell stimulatory factor-2, capable of specifically binding to the human B cell stimulatory factor-2; DNA coding for the above-mentioned receptor protein; expression vectors containing the above-mentioned DNA; host organisms transformed with the above-mentioned expression vector; a process for production of the receptor protein comprising culturing the host organisms in a medium to produce the receptor protein and recovering the receptor protein from the culture; and a antibody reacting with the protein.
    Type: Grant
    Filed: July 2, 1992
    Date of Patent: January 2, 1996
    Inventor: Tadamitsu Kishimoto
  • Patent number: 5459047
    Abstract: Purified BMP-6 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and/or cartilage defects and in wound healing and related tissue repair.
    Type: Grant
    Filed: May 27, 1994
    Date of Patent: October 17, 1995
    Assignee: Genetics Institute, Inc.
    Inventors: John M. Wozney, Elizabeth A. Wang, Vicki A. Rosen, Anthony J. Celeste
  • Patent number: 5457038
    Abstract: A novel homogeneous human cytokine, Natural Killer Stimulatory Factor, having the ability to induce the production of gamma interferon in vitro in human peripheral blood lymphocytes, and a pharmaceutical preparation containing it.
    Type: Grant
    Filed: September 18, 1990
    Date of Patent: October 10, 1995
    Assignee: Genetics Institute, Inc.
    Inventors: Giorgio Trinchieri, Bice Perussia, Michiko Kobayashi, Steven C. Clark, Gordon G. Wong, Rodney Hewick
  • Patent number: 5430135
    Abstract: The present invention relates, in general, to substantially pure preparations of the cynomolgus monkey hepatitis A viral isolates CY-145 and CY-55/JM-55; cDNAs of the genomic RNAs of cynomolgus monkey hepatitis A viral isolates CY-145 and CY-55/JM-55; a method of preventing hepatitis A in an animal; and vaccines comprising the cynomolgus monkey hepatitis A viral isolates CY-145 and CY-55/JM-55.
    Type: Grant
    Filed: July 6, 1993
    Date of Patent: July 4, 1995
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Omana V. Nainan, Harold S. Margolis, Betty H. Robertson, Margo A. Brinton, James W. Ebert
  • Patent number: 5416201
    Abstract: Mouse IgG.sub.1 inducing factor and the DNA that codes for the same were isolated by using a novel genetic technique, and their structures determined by the dideoxy chain termination method. The mouse IgG.sub.1 inducing factor obtained by the method of this invention has activity to improve immune response in living bodies and are hence useful for the treatment and prevention of infectious diseases, AIDS, functional immunodeficiency and the like. This factor, or part of its amino acid sequence, may also be used for the preparation of antibody against the same. In addition, it is possible to use this factor as a model for the synthesis of other polypeptides having similar structures, and for many other purposes.
    Type: Grant
    Filed: September 30, 1986
    Date of Patent: May 16, 1995
    Assignee: Tasuku Honjo
    Inventors: Tasuku Honjo, Eva Severinson
  • Patent number: 5405952
    Abstract: An analog human colony stimulating factor (hCSF) is disclosed, comprising a mutant amino acid sequence which is substantially homologous to the native sequence of an hCSF having at least one N-glycosylation site, wherein the mutant sequence comprises at least one amino acid substitution, deletion or insertion inactivating the N-glycosylation site.
    Type: Grant
    Filed: October 24, 1988
    Date of Patent: April 11, 1995
    Assignee: Immunex Corporation
    Inventors: Michael Deeley, Virginia L. Price, David Urdal
  • Patent number: 5382425
    Abstract: The present invention relates to a recombinant swinepox virus capable of replication comprising foreign DNA inserted into a site in the swinepox viral DNA which is not essential for replication of the swinepox virus. The invention further relates to homology vectors which produce recombinant swinepox viruses by inserting foreign DNA into swinepox viral DNA.
    Type: Grant
    Filed: January 13, 1992
    Date of Patent: January 17, 1995
    Assignee: Syntro Corporation
    Inventors: Mark D. Cochran, David E. Junker
  • Patent number: 5369025
    Abstract: A recombinant fowlpox virus is disclosed which is useful as a vaccine for protection against Marek's Disease. The recombinant virus preferably contains a gene for one or more Marek's Disease Virus antigens such as glycoprotein B homologue, glycoprotein C homologue, glycoprotein D homologue, glycoprotein H homologue and tegument proteins, under the control of a poxvirus promoter within a region of the DNA of fowlpox virus which is not essential for virus growth.
    Type: Grant
    Filed: December 10, 1991
    Date of Patent: November 29, 1994
    Assignees: The United States of America as represented by the Secretary of Agriculture, Nippon Zeon Co., Ltd.
    Inventors: Keyvan Nazerian, Lucy F. Lee, Noboru Yanagida, Ryohei Ogawa, Yi Li
  • Patent number: 5366875
    Abstract: Purified BMP-7 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and/or cartilage defects and in wound healing and related tissue repair.
    Type: Grant
    Filed: September 24, 1991
    Date of Patent: November 22, 1994
    Assignee: Genetics Institute, Inc.
    Inventors: John M. Wozney, Elizabeth A. Wang, Vicki A. Rosen
  • Patent number: 5364774
    Abstract: The present invention is concerned with vaccine for combating Treponema hyodysenteriae infection in swine containing proteins or polypeptides typical of the hemolysin protein of Treponema hyodysenteriae or containing recombinant polynucleotides having as part thereof a polynucleotide coding for said protein or polypeptide, and also is concerned with the preparation of said proteins, polypeptides and polynucleotides.
    Type: Grant
    Filed: October 21, 1992
    Date of Patent: November 15, 1994
    Assignee: Duphar International Research B.V.
    Inventors: Susie Jane Muir, Marcel B. H. Koopman, Johannes G. Kusters
  • Patent number: 5364773
    Abstract: What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant vaccinia virus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence. In one embodiment, the genetic functions are inactivated by deleting an open reading frame encoding a virulence factor. In another embodiment, the genetic functions are inactivated by insertional inactivation of an open reading frame encoding a virulence factor. What is also described is a vaccine containing the modified recombinant virus having nonessential virus-encoded genetic functions inactivated therein so that the vaccine has an increased level of safety compared to known recombinant virus vaccines.
    Type: Grant
    Filed: March 24, 1993
    Date of Patent: November 15, 1994
    Assignee: Virogenetics Corporation
    Inventors: Enzo Paoletti, Marion E. Perkus
  • Patent number: 5360894
    Abstract: This invention relates to a gene which codes for the IL-6 gene expression inducing nuclear factor C/EBP2 capable of binding sequence-specifically to the palindrome structure SEQ ID NO:2 located in the transcriptional regulatory region of the IL-6 gene; an expression plasmid with the C/EBP2 gene incorporated therein; an transformant harboring the expression plasmid; a recombinant C/EBP2 obtained by expressing the C/EBP2 gene; and a method of producing the recombinant C/EBP2.
    Type: Grant
    Filed: February 3, 1993
    Date of Patent: November 1, 1994
    Assignee: Tadamitsu Kishimoto
    Inventors: Tadamitsu Kishimoto, Toshio Hirano, Shizuo Akira, Hiroshi Isshiki, Osamu Tanabe, Shigemi Kinoshita, Takuya Shimamoto
  • Patent number: 5342774
    Abstract: The invention relates to an isolated DNA sequence which codes for an antigen expressed by tumor cells which is recognized by cytotoxic T cells, leading to lysis of the tumor which expresses it. Also described are cells transfected by the DNA sequence, and various therapeutic and diagnostic uses arising out of the properties of the DNA and the antigen for which it codes.
    Type: Grant
    Filed: December 12, 1991
    Date of Patent: August 30, 1994
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon, Pierre van der Bruggen, Benoit Van den Eynde, Aline Van Pel, Etienne De Plaen, Christophe Lurquin, Patrick Chomez, Catia Traversari
  • Patent number: 5324640
    Abstract: A cDNA and a chromosomal DNA coding for the human B-cell differentiation factor were provided and the entire nucleotide sequence of said DNAs as well as the entire amino acid sequences of the polypeptide portion of mature human B-cell differentiation factor and the leader peptide were revealed. The method for producing human B-cell differentiation factor by a recombinant gene technology was also provided.
    Type: Grant
    Filed: September 21, 1987
    Date of Patent: June 28, 1994
    Assignee: Suntory Limited
    Inventors: Tasuku Honjo, Kiyoshi Takatsu, Eva Severinson
  • Patent number: 5306627
    Abstract: An expression vector in which a DNA encoding a human neutrophil chemotactic factor polypeptide is inserted, a transformant (a host cell transformed with the expression vector), and a process for production of the said polypeptide by using the said transformant.
    Type: Grant
    Filed: June 4, 1991
    Date of Patent: April 26, 1994
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Masaaki Yamada, Ryuji Furuta, Junichi Yamagishi, Kouji Matsushima, Teizo Yoshimura
  • Patent number: 5283191
    Abstract: The invention is concerned with the MD18 and MD20 polypeptides of Marek's Disease virus which can be used to vaccinate poultry against MD.The invention also relates to nucleic acid sequences encoding the MD18 or MD20 polypeptides. Said sequences can be used for the preparation of a subunit or vector vaccine.
    Type: Grant
    Filed: July 10, 1992
    Date of Patent: February 1, 1994
    Assignee: Akzo N.V.
    Inventors: Robin W. Morgan, Johannes A. J. Claessens, Martha J. Willemse, Paulus J. A. Sondermeijer
  • Patent number: 5278049
    Abstract: DNA segments encoding two slightly different protease nexin I forms (PN-I.alpha. and PN-I.beta.) are cloned and expressed to provide practical quantities of PN-I for diagnostic and therapeutic use. PN-I is a serine protease inhibitor useful in controlling conditions mediated by proteolytic activity.
    Type: Grant
    Filed: March 13, 1987
    Date of Patent: January 11, 1994
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Joffre B. Baker, Randy W. Scott
  • Patent number: 5270199
    Abstract: Purified human mannose-binding protein and fragments thereof, nucleic acid producing these fragments, and vectors and cells including such nucleic acid are disclosed. The peptides and antibodies to those peptides are useful for diagnosis and treatment of disease.
    Type: Grant
    Filed: February 6, 1992
    Date of Patent: December 14, 1993
    Assignee: The Children's Medical Center Corporation
    Inventor: Raymond A. B. Ezekowitz
  • Patent number: 5268270
    Abstract: For the gene-technological production of proteins, a vector is introduced to gram-negative host cells which contains at least one gene coding translated. For the extracellular obtaining of the proteins its coding gene is so inserted into a vector which contains the IgA-protease precursor gene from micro-organisms of the genus Neisseria that the coding gene is positioned within the sequence of the IgA-protease precursor gene. A plasmid especially suitable for this purpose is the plasmid pIP100 contained in E. coli DSM 3775.
    Type: Grant
    Filed: February 29, 1988
    Date of Patent: December 7, 1993
    Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften c.V.
    Inventors: Thomas F. Meyer, Roman Halter, Johannes Pohlner
  • Patent number: 5268292
    Abstract: The invention is a process for cell propagation of hepatitis A virus. The process involves purifying a culture of hepatitis A virus particles. These hepatitis A virus particles are used for infecting cells being cultivated in a media. The hepatitis A particles suitable for use in this invention must have a cytopathic effect in the infected host cells that are selected for culturing the hepatitis A virus. After developing the cytopathic effect in the infected cells, the hepatitis A viruses produce degeneration and lysis in the infected cells and are released into the media. Isolation of the released hepatitis A virus then occurs. The preferred cells for use in this invention are FRhK4 (foetal rhesus monkey kidney) cells. The preferred virus particles for use in this invention are hepatitis A, strain HAS-15 particles have an antigen coded by a nucleotide sequence according to FIG. 1.
    Type: Grant
    Filed: September 6, 1991
    Date of Patent: December 7, 1993
    Inventors: Betty H. Robertson, Rhawna Khanna, Vicki Brown, Harold S. Margolis